Milestone Pharmaceuticals (NASDAQ:MIST) and Palisade Bio (NASDAQ:PALI) Financial Review

Milestone Pharmaceuticals (NASDAQ:MIST) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Milestone Pharmaceuticals and Palisade Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1	1	4	1	2.71
Palisade Bio	1	0	7	2	3.00

Milestone Pharmaceuticals presently has a consensus target price of $6.40, indicating a potential upside of 574.11%. Palisade Bio has a consensus target price of $9.00, indicating a potential upside of 339.02%. Given Milestone Pharmaceuticals’ higher probable upside, research analysts clearly believe Milestone Pharmaceuticals is more favorable than Palisade Bio.

Insider & Institutional Ownership

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Palisade Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Milestone Pharmaceuticals and Palisade Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%
Palisade Bio	N/A	-33.47%	-31.79%

Volatility & Risk

Milestone Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500.

Earnings & Valuation

This table compares Milestone Pharmaceuticals and Palisade Bio”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$2.34 million	50.45	-$63.06 million	($0.69)	-1.38
Palisade Bio	$500,000.00	714.51	-$16.78 million	($0.48)	-4.27

Palisade Bio has lower revenue, but higher earnings than Milestone Pharmaceuticals. Palisade Bio is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Palisade Bio beats Milestone Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

About Palisade Bio

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.